Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, ENANTA PHARMACEUTICALS INC reported revenue of $65M, down 3.4% year over year. Operating margin was -130.7% and net margin -125.4%, on a free-cash-flow margin of -49.2% with capital expenditure at 19.7% of revenue. Every figure is computed directly from ENTA's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $65M | -130.7% | -125.4% |
| FY2024 | $68M | -179.9% | -171.6% |
| FY2023 | $79M | -173.2% | -169.0% |
| FY2022 | $86M | -143.7% | -141.3% |
| FY2021 | $97M | -112.9% | -81.4% |
How does ENTA compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.